Home→Health Topics→Neurological→CBG, Brain Injury, and Neuroinflammation

Health Topics — Neurological

CBG, Brain Injury, and Neuroinflammation: What the Preclinical Research Shows

The secondary injury cascade after traumatic brain injury involves neuroinflammation and oxidative stress — and CBG has been studied in several preclinical models of both.

Standard Research Article · Neurological · Last Reviewed: September 2026 · ~1,200 words

Evidence Level: Tier 2 — Preclinical · Animal Models and In Vitro Data Only · No Human TBI Trials

Illustration placeholder — cbg-brain-injury-neuroinflammation.png

The Biology of Brain Injury

The Injury That Keeps Happening After the Injury

Traumatic brain injury — TBI — is better understood today as a process rather than an event. The initial impact causes what researchers call the primary injury: direct mechanical damage to neural tissue. But what follows in the hours, days, and weeks after that impact is often where the lasting harm is determined.

The secondary injury cascade involves a coordinated breakdown of systems: neuroinflammation as immune cells flood the damaged tissue, oxidative stress as reactive oxygen species accumulate beyond the brain's capacity to neutralize them, disruption of the blood-brain barrier, excitotoxicity from uncontrolled glutamate release, and cell death from both necrosis and apoptosis. These mechanisms interact and amplify each other. The primary injury creates the initial damage; the secondary cascade often determines how much of that damage becomes permanent.

This is the context in which cannabinoid research on TBI operates. Because the secondary cascade involves inflammation, oxidative stress, and cell death pathways that cannabinoids have demonstrated effects on in other contexts, researchers have investigated whether cannabinoids might have a role in modulating what happens after the primary injury. The research to date is preclinical. But the mechanisms are coherent and the findings are worth examining carefully.

CBD Research in Brain Injury

What CBD Research Has Found in TBI Models

CBD has been the more extensively studied cannabinoid in TBI preclinical research. A 2024 study published in a peer-reviewed neurology journal examined CBD's effects in a rat TBI model, finding that CBD treatment was associated with reduced brain edema, improved blood-brain barrier permeability, and reductions in inflammatory markers. A 2024 review in Frontiers in Neurology described CBD's pharmacological profile as relevant to multiple mechanisms in the secondary injury cascade — anti-inflammatory activity, antioxidant properties, modulation of excitotoxicity, and effects on the blood-brain barrier.

A 2026 study published in Cellular and Molecular Biology Letters examined CBD in a TBI model and found it reduced neuronal damage and cognitive deficits in rodents through effects on a specific oxidative stress pathway — the TRPV1 channel, which is also a known target of CBG. Another 2024 study found CBD reduced cortical tissue degeneration and traumatic hemorrhaging in a mouse model by improving intracranial lymphatic drainage.

Field Note

All TBI cannabinoid research to date is preclinical — animal models and cell studies. No randomized controlled trials in human TBI patients have been completed. Some clinical trials are underway, including studies sponsored by professional sports organizations, but results are not yet published. The mechanism evidence is coherent; the clinical evidence does not yet exist.

CBG and Neuroinflammation

What CBG Research Has Found in Neuroinflammation Models

CBG-specific research on brain injury is earlier in development than the CBD literature, but several findings are relevant. A 2025 study — published in the International Journal of Molecular Sciences — examined CBG in a mouse model of global cerebral ischemia, a model of acute brain injury caused by interrupted blood flow. The researchers found that CBG attenuated ischemia-induced memory deficits, reduced neuronal loss in the hippocampus, and reduced markers of neuroinflammation and microglial activation. The authors proposed that CBG's neuroprotective effects in this model were mediated through reductions in neuroinflammation and modifications in neuronal plasticity markers.

A 2026 review published in Frontiers in Pharmacology — focused primarily on CBG and drug-resistant epilepsy — synthesized the preclinical neuroprotection evidence for CBG across multiple models. The review identified several mechanisms through which CBG appears to act: anti-inflammatory activity through PPARγ activation, antioxidant effects including maintenance of the Nrf2 pathway that regulates cellular antioxidant response, and direct effects on neuronal survival in oxidative stress models. At low micromolar concentrations in cell studies, CBG sustained neuronal viability under conditions of combined oxidative and amyloidogenic stress.

An earlier in vitro study using motor neuron cells found that CBG pre-treatment inhibited apoptosis, reduced oxidative stress markers, and restored the Nrf2 pathway — the primary cellular mechanism for responding to oxidative injury. The authors concluded the findings were consistent with neuroprotective activity. A separate microglial study presented more mixed results: at lower concentrations CBG showed anti-inflammatory effects in microglial cells, but at higher concentrations it altered microglial morphology and failed to attenuate certain inflammatory markers. This finding illustrates why the preclinical data requires careful reading — concentration, timing, and model type all affect what is observed.

CBG and CBD Together

The Combination Signal

A 2026 ScienceDirect study examining CBD:THC ratios in TBI noted in passing that their CBD preparation also contained CBG, CBC, and CBN in unknown amounts, and specifically referenced research showing that these minor cannabinoids combined with CBD can inhibit aldose reductase — an enzyme implicated in oxidative injury. This is not a CBG-specific TBI finding, but it is consistent with what the broader neuroprotection literature suggests: that CBG may contribute meaningfully to the activity of whole-plant preparations in neuroinflammatory contexts, without being the sole mechanism.

This is one reason why isolate-versus-whole-plant comparisons matter in this research domain. Studies examining CBD alone and studies examining preparations that also contain CBG, CBC, and CBN may be measuring different things — not because of some loosely defined "entourage effect," but because specific minor cannabinoids have documented pharmacological activity on pathways relevant to secondary brain injury.

What This Research Does and Does Not Establish

The preclinical evidence suggests CBG has activity on pathways involved in the secondary injury cascade after brain injury — neuroinflammation, oxidative stress, and neuronal survival. These findings come from animal models and cell studies, not from human TBI patients. Animal models of brain injury have a poor track record of translating to effective human treatments. Many compounds that show promise in preclinical TBI research have failed in clinical trials.

No one should use a CBG preparation as a treatment for traumatic brain injury. TBI is a serious medical condition requiring emergency medical care and professional neurological management. The research described here is mechanistic and exploratory — it examines how CBG interacts with injury pathways in controlled laboratory conditions, not how it performs as a clinical intervention in living human patients.

The research is worth following. The clinical evidence does not yet exist.

Related Research — Neurological

CBG and Neuroprotection: The Preclinical Evidence

Standard Research · Neurological — the broader neuroprotection evidence base for CBG across multiple preclinical models.

CBG in Huntington's Disease Research

Standard Research · Neurological — one of the more developed preclinical evidence domains for CBG neuroprotection.

Neuroinflammation and Cannabinoids

Standard Research · Neurological — the neuroinflammation mechanisms that cannabinoids appear to modulate.

Compound Reference

CBG Monograph

Monograph — full pharmacological profile for CBG including receptor mechanisms and neuroprotection evidence summary.

Endocannabinoid Receptors: CB1, CB2, and Beyond

Foundational · Understanding ECS — the receptor targets relevant to CBG's neurological activity.

References

  1. Cao Y, et al. Cannabidiol alleviates the inflammatory response in rats with traumatic brain injury through the PGE2-EP2-cAMP-PKA signaling pathway. Acta Biochim Biophys Sin. 2025;57(5):758–769.
  2. Dong S, et al. Cannabidiol alleviates neurological deficits after traumatic brain injury by improving intracranial lymphatic drainage. J Neurotrauma. 2024.
  3. Xu Y, et al. Cannabidiol alleviates traumatic brain injury-induced neuronal damage and cognitive deficits by inhibiting ferroptosis via the TRPV1/MCU/PI3K/Akt pathway. Cell Mol Biol Lett. 2026.
  4. Aychman MM, Goldman DL, Kaplan JS. Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries. Front Neurol. 2023;14:1087011.
  5. Montalvo-Capocci H, et al. Cannabigerol attenuates memory impairments, neurodegeneration, and neuroinflammation caused by transient global cerebral ischemia in mice. Int J Mol Sci. 2025;26(16):8056.
  6. Morè L, et al. Elucidating the putative role of cannabigerol: a hypothesis-generating review of neuroinflammatory and neuroprotective mechanisms with implications for drug-resistant epilepsy. Front Pharmacol. 2026.
  7. Gugliandolo A, et al. In vitro model of neuroinflammation: efficacy of cannabigerol, a non-psychoactive cannabinoid. Int J Mol Sci. 2018;19(7):1992.
  8. Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. PubMed. 2025 [PMID 41548647].

J.P. Hemp Company · Research Archive · Neurological · Last Reviewed: September 2026

These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease. The research described in this article is preclinical. Consult a qualified healthcare professional before using any hemp preparation, particularly if you or someone you care for has experienced a traumatic brain injury.